Canadian advocacy group 'TheraPsil' push to legalize therapeutic psilocybin

Emerging Research
Written By

TheraPsil is a non-profit coalition dedicated to helping Canadians in medical need access legal, psilocybin-assisted psychotherapy to treat end-of-life distress.

"Our initial focus is on the provision of compassionate treatment for Canadians in palliative care who suffer from end-of-life distress. End-of-life distress is best described as the combination of anxiety, depression, hopelessness, and demoralization experienced by patients who receive a diagnosis of an incurable illness, or who are in remission from diseases such as cancer, HIV/AIDS, or heart disease. As research in psychedelic therapy matures, we will further expand our services to include others who may benefit from psilocybin."

For more psychedelic news and research, visit the psychedelic health professional network homepage.

Previous

Increases in psychological flexibility mediate relationship between acute psychedelic effects and decreases in racial trauma symptoms among people of color
Next

Two models of legalization of psychedelic substances: Reasons for concern